LONA:NASDAQ
LeonaBio Inc
5,83 USD
arrow_upward
+1,39%(+0,080) 1D
7. lis, 16:00:01 GMT -4 · USD
search
Svi simboli
| Simbol | Cijena | Promjena | Postotna promjena |
|---|
insights_autoGeneriranje najvažnijih uvida za LONA...
Otvori
5,77 USD
Najviša
6,21 USD
Najniža
5,61 USD
Trž. kap.
54,93 mil.
Prosj. kol.
332,52 tis.
Količina
178,06 tis.
52-tjed. najviša
14,19 USD
52-tjed. najniža
2,21 USD
EPS
−19,72 USD
Beta
2,11
Dionice u optjecaju
9,42 mil.
Broj djelatnika
19
Otvori
5,77 USD
Najviša
6,21 USD
Najniža
5,61 USD
Trž. kap.
54,93 mil.
Prosj. kol.
332,52 tis.
Količina
178,06 tis.
52-tjed. najviša
14,19 USD
52-tjed. najniža
2,21 USD
EPS
−19,72 USD
Beta
2,11
Dionice u optjecaju
9,42 mil.
Broj djelatnika
19
Vijesti
Iz web-izvora i od partnera za vijesti
Naslovi.net
·
prije 1 dan
Wall Street: Nasdaq na novom rekordu
Financije.hr
·
prije 9 sati
Wall Street pred otvaranjem: S&P 500 i Nasdaq zastali na vrhu, prinosi vraćaju oprez
Lider Media
·
prije 16 sati
Na Wall Streetu rekord S&P 500 indeksa
MarketBeat
·
prije 18 minuta
Workday (NASDAQ:WDAY) Insider Sells 2,729 Shares of Company Stock
Profil
Athira Pharma is a late clinical stage American biopharmaceutical company developing small-molecule therapeutics targeting neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. The company's lead candidate, ATH-1017, is in human studies for Alzheimer's disease as of 2021.
The company was founded in 2011 and is headquartered in Seattle. Funding that supports the company is from both public and private investment groups including the Alzheimer's Drug Discovery Foundation, Dolby Family Ventures, the State of Washington's Life Sciences Discovery Fund, The W Fund, WRF Capital, and other private investors.
Leen Kawas served as the company's first President and CEO, but resigned in October 2021, after an independent special committee found she "altered images in scientific papers she authored." In 2025, the company paid a $4 million settlement in relation to allegations that the CEO falsified research to secure a federal grant. On October 21, 2021, Mark Litton, Ph.D., M.B.A. became chief executive officer. Wikipedia
LeonaBio Inc – informacije
Glavni izvršni direktor-
Zaposlenici19
Osnovano2011
SjedišteBothell, Washington, Sjedinjene Američke Države
Sektor-
Web-lokacijaleonabio.com